MediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to Panama

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire MediPharm Labs Expands Its International Medical Cannabis Footprint with First CBD Metered-Dose Inhaler Shipment to PanamaAuthor of the article:MediPharm has completed its first shipment to Adeiwa Pharma, which will distribute the product to patients in Panama.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO, Oct. 13, 2026 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its entry into Panama’s medical cannabis market with a first commercial shipment to Adeiwa Pharma. The initial shipment of CBD metered-dose inhalers represents MediPharm’s first sale into the country and extends an international footprint that spans shipments to more than 10 countries and regions, including Germany, the United Kingdom, France, Australia, New Zealand, Brazil and the United States.This advertisement has not loaded yet, but your article continues below.Adeiwa Pharma will use its distribution and clinic relationships to support access for patients in Panama, with the products expected to reach patients this month.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try again“We are pleased to announce MediPharm’s first commercial sale into Panama and another important expansion of our international medical business,” said Greg Hunter, Interim Chief Executive Officer and Chief Financial Officer of MediPharm Labs. “Each new market builds on the regulatory credentials and pharmaceutical manufacturing capabilities we have established over many years. We look forward to working with Adeiwa Pharma to bring our CBD metered-dose inhaler to patients in Panama and to continue expanding access to high-quality cannabinoid medicines in regulated international markets.”The CBD metered-dose inhaler is manufactured using pharmaceutical-grade cannabidiol active pharmaceutical ingredient (“API”) and is a smoke-free cannabinoid delivery system designed to deliver a precise, repeatable dose through a familiar pharmaceutical device.Under Panama’s medical cannabis framework, established by Law 242 of 2021 and its implementing regulations, the National Directorate of Pharmacy and Drugs has authorized the importation of MediPharm’s CBD metered-dose inhaler under an exception to sanitary registration, allowing the product to be supplied through authorized private pharmacies.This advertisement has not loaded yet, but your article continues below.The shipment comes as regulated medical cannabis markets continue to develop across Latin America. One independent market estimate projects the Latin American medical cannabis market to reach approximately US$581.5 million by 2030, compared with US$78.1 million in 2023, representing a projected compound annual growth rate of 33.2% from 2024 to 2030.¹ The Company continues to evaluate opportunities to introduce innovative cannabinoid dosage formats into regulated international markets where its GMP credentials and pharmaceutical manufacturing capabilities support market access.Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices Licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the Company’s current foreign drug manufacturing site registration with the U.S. FDA. MediPharm also has EU-GMP certification, ANVISA GMP certification from Brazil and TGA compliance in Australia.In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm’s reach to medical patients in Canada through the Canna Farms medical e-commerce platform and in Australia and Germany through Beacon Medical Pty. Ltd. and Beacon Medical GmbH. The acquisition also included Harvest Medical Clinics in Canada, which provides medical cannabis patients with physician consultations, education and prescriptions.The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.This advertisement has not loaded yet, but your article continues below.For further information, please contact:MediPharm Labs Investor Relations1-416-913-7425investors@medipharmlabs.comCautionary Note Regarding Forward-Looking InformationThis news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the expected availability of the CBD metered-dose inhalers to patients in Panama beginning in October 2026; Adeiwa Pharma’s ability to support patient access through its distribution and clinic relationships; demand for the product and for pharmaceutical-quality cannabinoid medicines; the development of the Panamanian and Latin American medical cannabis markets, including estimates of the size and growth of the Latin American medical cannabis market; future international sales and market expansion; and the ability of MediPharm’s GMP credentials, pharmaceutical-grade APIs and manufacturing capabilities to support further international opportunities. The material assumptions underlying these forward-looking statements include, but are not limited to, the continued validity of the import authorization described in this news release, Adeiwa Pharma’s ability to distribute the product as planned, the continuation of the Company’s commercial relationships, and the Company’s ability to manufacture and supply products in accordance with applicable GMP requirements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the delay or failure to receive regulatory approvals; delays in product distribution or patient availability; changes in applicable laws, regulations, regulatory interpretations, prescribing requirements or import authorizations; the accuracy of third-party market estimates; and other factors discussed in MediPharm’s filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.SOURCE MediPharm Labs Corp.¹ Grand View Research, Latin America Medical Marijuana Market Size & Outlook, 2030. Market figures cited are regional estimates and are not specific to Panama.This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.